The long road: improving outcome in elderly "unfit" AML?

Bob Lowenberg*, Gerwin Huls

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Abstract

In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.

Original languageEnglish
Pages (from-to)2114-2115
Number of pages3
JournalBlood
Volume135
Issue number24
DOIs
Publication statusPublished - 11-Jun-2020

Keywords

  • LOW-DOSE CYTARABINE
  • PLACEBO

Cite this